ISRG · News · 20260814N
Competition and New Entrants
INTUITIVE SURGICAL INC · 2026-08-14 · Importance 44 · Surprise 60 · In source text
Johnson & Johnson’s Ottava surgical-robotics system received authorization from the U.S. Food and Drug Administration, introducing a new competitor to Intuitive Surgical’s da Vinci systems. Ottava’s space-saving design and integration with Johnson & Johnson’s existing surgical tools could pressure Intuitive Surgical’s U.S. installed base and recurring revenue. The reported impact will depend on Ottava’s hospital placements and procedure volumes, which investors are expected to monitor in upcoming earnings reports.
Key facts
- Intuitive Surgical (ISRG) is facing new competition in the U.S. surgical robotics market as Johnson & Johnson's Ottava system received FDA authorization. source
- Ottava's space-saving design and integration with J&J's existing surgical tools pose a direct challenge to Intuitive Surgical's da Vinci systems, potentially impacting its recurring revenue and installed base. source
- Intuitive Surgical Inc.'s stock closed 34.67% below its 52-week high, which was set on January 7th. source
- Intuitive Surgical Inc. (ISRG) shares fell 1.68% to $394.51 on Friday. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | Intuitive Surgical (ISRG) is facing new competition in the U.S. surgical robotics market as Johnson & Johnson's Ottava system received FDA… |